Harman Finochem Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Harman Finochem Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $11.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Harman Finochem Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $11.4M Trade | TransData Nexus

Harman Finochem Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $11.4M Total Trade · DGFT Verified

Harman Finochem Limited is an Indian pharmaceutical exporter with a total trade value of $11.4M across 3 products in 3 therapeutic categories. Based on 526 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metformin ($6.9M), Allopurinol ($3.4M), Bisoprolol ($1.1M).

Harman Finochem Limited — Export Portfolio & Destination Treemap

Harman Finochem Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Harman Finochem Limited? — Company Overview & Market Position

Harman Finochem Limited, established on March 17, 1983, is a Mumbai-based pharmaceutical company specializing in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company operates under the Corporate Identification Number (CIN) U24110MH1983PLC029560 and is registered as a public limited company in Mumbai, Maharashtra.

The authorized share capital of Harman Finochem Limited is ₹50 million, with a paid-up capital of ₹47.636 million, reflecting a promoter holding of approximately 92.83% as of 2023. The company employs around 1,772 individuals as of April 9, 2024. Harman Finochem Limited's website is www.harmanfinochem.com.

What Does Harman Finochem Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metformin$6.9M 2Allopurinol$3.4M

Product Portfolio — Top 3 by Export Value

Harman Finochem Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metformin	Diabetes & Endocrine	$6.9M	295	1.5%	15
2	Allopurinol	Lipid & Metabolism	$3.4M	80	0.7%	6
3	Bisoprolol	Cardiovascular	$1.1M	151	1.4%	9

Harman Finochem Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $11.4M. The top category is Diabetes & Endocrine (60.3% of portfolio), followed by Lipid & Metabolism (29.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Harman Finochem Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Harman Finochem Limited operates two state-of-the-art manufacturing facilities in Aurangabad, Maharashtra, with a combined production capacity of 350,000 liters. These facilities are compliant with current Good Manufacturing Practices (cGMP) and have been inspected by international regulatory bodies, including the USFDA, EU, PMDA, KFDA, TGA, ANVISA, and PIC/s. (pharmasource.global)

3Key Leadership

The company is led by Chairman and Managing Director Mr. Bhupinder Singh Manhas, who founded Harman Finochem Limited in 1983. Other key executives include Inderjeet Kaur Bhupinder Singh, Harpreet Singh Bhupinder Singh, Gurpreet Singh Minhas, and Savreen Minhas.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Harman Finochem Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Harman Finochem Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are inspected and comply with cGMP norms as per USFDA, ICH Q7A, TGA, PIC, WHO-GMP, Schedule M, and Japanese Foreign Accreditation. (pharmasource.global) The company has submitted Drug Master Files (DMFs) for several APIs to the USFDA and is awaiting facility approval.

2Emerging Markets

Harman Finochem Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are WHO-GMP certified, facilitating access to these regions.

3Geographic Strategy

The company's export portfolio is highly concentrated, with the top five products accounting for 100% of total exports. This indicates a lack of diversification, which may expose Harman Finochem Limited to risks associated with market fluctuations in these specific products.

Harman Finochem Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Harman Finochem Limited has submitted Drug Master Files (DMFs) for several APIs to the USFDA and is awaiting facility approval. The company's manufacturing facilities are inspected and comply with cGMP norms as per USFDA standards. (pharmasource.global)

2WHO & EU GMP

The company's manufacturing facilities are WHO-GMP certified, facilitating access to emerging markets. Additionally, Harman Finochem Limited has received EU GMP approval for its formulation facility of Oral Solid Dosages.

3CDSCO & Indian Regulatory

Harman Finochem Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers. The company has also been awarded the certificate of recognition as an export house by the Ministry of Commerce, Government of India, for its meritorious contribution in the field of API exports.

Recent Regulatory Actions

Harman Finochem Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Harman Finochem Limited operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not available, the company's focus on APIs and chemical intermediates positions it alongside other manufacturers in the sector.

2Key Differentiators

Harman Finochem Limited's key differentiators include its specialization in over 45 APIs, including Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, and Glycopyrrolate/Glycopyrronium bromide. The company operates two GMP-certified manufacturing sites in Aurangabad, maintaining a combined production capacity of 350,000 liters.

3Strategic Position

Harman Finochem Limited's current strategic direction focuses on the manufacturing and export of APIs, with an emphasis on quality and compliance with international standards. The company's future outlook includes expanding its product portfolio and exploring new markets to enhance its global presence.

Buyer Due Diligence Brief — Evaluating Harman Finochem Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Harman Finochem Limited has a track record of exporting APIs to over 75 countries worldwide. The company's manufacturing facilities are inspected and comply with cGMP norms as per USFDA, ICH Q7A, TGA, PIC, WHO-GMP, Schedule M, and Japanese Foreign Accreditation. (pharmasource.global) The company has been awarded the certificate of recognition as an export house by the Ministry of Commerce, Government of India, for its meritorious contribution in the field of API exports.

2Certifications to Verify

Importers should verify the following certifications when considering Harman Finochem Limited as a supplier:

FDA Registration: Confirm the company's registration status with the US Food and Drug Administration (FDA) through the FDA's official website.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practices (WHO-GMP) certification by consulting the WHO's official website.

Frequently Asked Questions — Harman Finochem Limited

How many pharmaceutical products does Harman Finochem Limited export from India?

Harman Finochem Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Metformin ($6.9M), Allopurinol ($3.4M), Bisoprolol ($1.1M). Total export value is $11.4M.

What is Harman Finochem Limited's total pharmaceutical export value?

Harman Finochem Limited's total pharmaceutical export value is $11.4M, based on 526 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Harman Finochem Limited cover?

Harman Finochem Limited exports across 3 therapeutic categories. The largest are Diabetes & Endocrine (60.3%, 1 products), Lipid & Metabolism (29.7%, 1 products), Cardiovascular (10.0%, 1 products).

Get Full Harman Finochem Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.